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Reply:
We thank Drs. Jaeschke and Du for their comments and insight
regarding our recent manuscript highlighting a protective role for
benzyl alcohol (BA) in a murine model of acetaminophen-induced
liver injury. We appreciate their attention to our findings and agree
that the time course of protection of BA in this preclinical model
suggests a limited utility of BA as a potential late therapeutic sub-
sequent to acetaminophen overdose. However, our interest in acute
sterile liver injury, including acetaminophen-induced hepatotoxicity,
continues to stimulate our investigations into the understanding of
innate immune signaling in liver injury, as well as the role of BA
and other therapeutics to influence these immune responses.
Moreover, we agree that the protective effects of BA in this pre-
clinical model may be greatly influenced by inhibition of P450
enzymatic activity. However, the findings that the hepatoprotective
influence of BA in this model was lost in mice deficient in Toll-
like receptor 4 (TLR4), and, more specifically, in mice deficient in
TLR4 expression on myeloid cells, suggests a role for modulation
of innate immune signaling as a contributive mechanism.
With regard to the role of inflammasome signaling and
acetaminophen-induced liver injury, our findings of decreased liver
injury in mice lacking Nalp3 or caspase-1 expression were consistent
with those of other investigators, as pointed out in Drs. Jaeschke
and Du’s letter. We agree that the levels of interleukin (IL)-1b
were modest and may not contribute substantially to liver injury in
acetaminophen toxicity. Additionally, hepatocytes express and acti-
vate the inflammasome, but do not produce IL-1b or IL-18 at high
levels, thus the complexity of inflammasome signaling may not be
solely dependent upon these cytokines. Therefore, further investiga-
tion of the role of the inflammasome and other pattern recognition
receptors should be further investigated for their role in contributing
to the pathophysiology in sterile liver injury, as well as the potential
to target these receptors for therapeutic benefit.
Again, we appreciate their comments and the opportunity to
respond.
BRIAN S. ZUCKERBRAUN, M.D.
CHANGCHUN CAI, M.D., PH.D.
TIMOTHY R. BILLIAR, M.D.
Department of Surgery
University of Pittsburgh
Pittsburgh, PA
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Relationship Between Vitamin D Status and Response to Hepatitis C Virus Therapy
To the Editor:
We read with interest the recently published meta-analysis by
Garc!ıa-!Alvarez et al.1 evaluating vitamin D status and sustained
virological response (SVR) to interferon-based antiviral therapy in
chronic hepatitis C virus with or without human immunodefi-
ciency virus coinfection. They found that a 25-hydroxyvitamin D
(25[OH]D) level <20 ng/mL was associated with lower odds of
achieving SVR (odds ratio5 0.53, 95% confidence interval 0.34-
0.67) in 1406 patients. We performed a similar meta-analysis in a
larger cohort of 2605 hepatitis C virus–monoinfected patients but
contrarily found no association between mean 25(OH)D level and
SVR (odds ratio5 1.44, 95% confidence interval 0.92-2.26;
P5 0.11).2
While the two meta-analyses differ in their inclusion of human
immunodeficiency virus–infected patients, we note that similar
findings of a relationship between SVR and 25(OH)D level were
obtained in their subgroup analysis of hepatitis C virus monoin-
fection. We therefore suggest that the discordance of findings
between the two studies likely arises from some methodologic
flaws in their study. First, three of the 11 studies included in the
SVR meta-analysis related to the same Italian cohort of approxi-
mately 200 patients,3-5 meaning that each patient from this
cohort has been evaluated three times. In total their SVR meta-
analysis involved 1010 patients when studies evaluating the same
cohort of patients multiple times are excluded. Second, five large
studies from Europe and Australia, four of which were published
in detail by us and involved a combined total of 1569 patients,
were not included in the meta-analysis despite being readily iden-
tifiable using the stated search strategy. Third, the meta-analysis
included only studies in which 25(OH)D level was assessed as a
categorical rather than continuous variable. This is subject to
potential bias as standard definitions for vitamin D insufficiency
and deficiency vary worldwide and according to the unit of mea-
surement. Fourth, one included study involved patients receiving
vitamin D supplementation despite this being a stated exclusion
criterion. Finally, none of the above issues were formally
addressed anywhere in the manuscript as caveats to the study’s
conclusions.
These methodologic issues, particularly in reference to the key
studies included and excluded, cast doubt on the validity of their
findings, which the reader should be aware of when evaluating the
study’s positive conclusions.
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Reply:
We appreciate the interest of Kitson et al. in our recent article.1
We found an association between the cutoff of 20 ng/mL of
25-hydroxyvitamin D (25[OH]D) and sustained virologic response
in patients on pegylated interferon-a/ribavirin therapy (odds
ratio5 0.53, 95% confidence interval 0.31-0.91), which is in
disagreement with the meta-analysis published by Kitson et al.
Thus, these authors suggested some issues that should be clarified.
Firstly, Kitson et al. pointed out that our analysis included three differ-
ent studies with the same Italian cohort.2-4 However, these studies were
published by prestigious journals during consecutive years and provided
independent and remarkable information, each of them including a differ-
ent number of patients. Nevertheless, the significant association was lost if
we reanalyzed it considering only one of these studies.
Secondly, with regard to the studies that were not included in
our meta-analysis, we carefully selected articles from PubMed,
SCOPUS, LILACS, and the Cochrane Library. When data were
unclear, incomplete, or not explicitly reported, we contacted the
corresponding author up to three times in order to obtain addi-
tional information. Unfortunately, some authors did not reply or
refused to provide the requested data.
Thirdly, we only included studies in which vitamin D was
assessed as a categorical variable (the thresholds for deficiency, sub-
optimal, and optimal 25[OH]D levels) because we considered that
it was more relevant and useful than the continuous variable.
Nevertheless, we appreciate the suggestion, and we will take it into
account for future analyses.
Fourthly, we included a study5 with a reduced percentage of
patients (35%) receiving vitamin D supplementation. When we
excluded this report, the odds ratio value did not change signifi-
cantly (odds ratio5 0.58, 95% CI 0.32-0.99).
Finally, it is noteworthy that the two meta-analyses have sought
the same goal from different perspectives. Kitson et al.C¸s meta-
analysis included seven articles and four conference abstracts, while
our meta-analysis included 11 studies. Only two articles were ana-
lyzed in both meta-analyses. Both studies showed differences in the
inclusion/exclusion criteria and in the analysis strategy; thus, Kitson
et al. compared baseline levels of 25(OH)D, but we analyzed
the data considering several thresholds frequently used to define
25(OH)D status in clinical practice. For these reasons, we consider
that both studies are complementary and might be useful.
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Is Pentoxifylline Still an Option in Severe Alcoholic Hepatitis?
To the Editor:
We read with interest the Hepatology Elsewhere piece by Cabal-
leria1 describing the study by Park et al. that investigated the rela-
tive efficacies of prednisolone and pentoxyfylline in acute alcoholic
hepatitis in a noninferiority study.2 Caballeria states that the trial
concluded that the efficacy of pentoxifylline is lower than that of
prednisolone. However, the noninferiority endpoint of that study
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